SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(De Backer Guy) "

Sökning: WFRF:(De Backer Guy)

  • Resultat 41-44 av 44
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
41.
  • Rosseel, Liesbeth, et al. (författare)
  • Contemporary European practice in transcatheter aortic valve implantation: results from the 2022 European TAVI Pathway Registry.
  • 2023
  • Ingår i: Frontiers in cardiovascular medicine. - 2297-055X. ; 10
  • Tidskriftsartikel (refereegranskat)abstract
    • A steep rise in the use of transcatheter aortic valve implantation (TAVI) for the management of symptomatic severe aortic stenosis occurred. Minimalist TAVI procedures and streamlined patient pathways within experienced Heart Valve Centres are designed to overcome the challenges of ever-increasing procedural volume.The 2022 European TAVI Pathway Survey aims to describe contemporary TAVI practice across Europe.Between October and December 2022, TAVI operators from 32 European countries were invited to complete an online questionnaire regarding their current practice.Responses were available from 147 TAVI centres in 26 countries. In 2021, the participating centres performed a total number of 27,223 TAVI procedures, with a mean of 185 TAVI cases per centre (median 138; IQR 77-194). Treatment strategies are usually (87%) discussed at a dedicated Heart Team meeting. Transfemoral TAVI is performed with local anaesthesia only (33%), with associated conscious sedation (60%), or under general anaesthesia (7%). Primary vascular access is percutaneous transfemoral (99%) with secondary radial access (52%). After uncomplicated TAVI, patients are transferred to a high-, medium-, or low-care unit in 28%, 52%, and 20% of cases, respectively. Time to discharge is day 1 (12%), day 2 (31%), day 3 (29%), or day 4 or more (28%).Reported adoption of minimalist TAVI techniques is common among European TAVI centres, but rates of next-day discharge remain low. This survey highlights the significant progress made in refining TAVI treatment and pathways in recent years and identifies possible areas for further improvement.
  •  
42.
  • Rydén, Lars, et al. (författare)
  • ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
  • 2013
  • Ingår i: European Heart Journal. - : Oxford University Press (OUP). - 0195-668X .- 1522-9645. ; 34:39, s. 3035-3087
  • Tidskriftsartikel (refereegranskat)abstract
    • This is the second iteration of the European Society of Cardiology (ESC) and European Association for the Study of Diabetes (EASD) joining forces to write guidelines on the management of diabetes mellitus (DM), pre-diabetes, and cardiovascular disease (CVD), designed to assist clinicians and other healthcare workers to make evidence-based management decisions. The growing awareness of the strong biological relationship between DM and CVD rightly prompted these two large organizations to collaborate to generate guidelines relevant to their joint interests, the first of which were published in 2007. Some assert that too many guidelines are being produced but, in this burgeoning field, five years in the development of both basic and clinical science is a long time and major trials have reported in this period, making it necessary to update the previous Guidelines.
  •  
43.
  • Zannad, Faiez, et al. (författare)
  • Prevention of cardiovascular disease guided by total risk estimations - challenges and opportunities for practical implementation: highlights of a CardioVascular Clinical Trialists (CVCT) Workshop of the ESC Working Group on CardioVascular Pharmacology and Drug Therapy.
  • 2012
  • Ingår i: European Journal of Preventive Cardiology. - : Oxford University Press (OUP). - 2047-4873 .- 2047-4881. ; 19:6, s. 1454-1464
  • Forskningsöversikt (refereegranskat)abstract
    • This paper presents a summary of the potential practical and economic barriers to implementation of primary prevention of cardiovascular disease guided by total cardiovascular risk estimations in the general population. It also reviews various possible solutions to overcome these barriers. The report is based on discussion among experts in the area at a special CardioVascular Clinical Trialists workshop organized by the European Society of Cardiology Working Group on Cardiovascular Pharmacology and Drug Therapy that took place in September 2009. It includes a review of the evidence in favour of the 'treat-to-target' paradigm, as well as potential difficulties with this approach, including the multiple pathological processes present in high-risk patients that may not be adequately addressed by this strategy. The risk-guided therapy approach requires careful definitions of cardiovascular risk and consideration of clinical endpoints as well as the differences between trial and 'real-world' populations. Cost-effectiveness presents another issue in scenarios of finite healthcare resources, as does the difficulty of documenting guideline uptake and effectiveness in the primary care setting, where early modification of risk factors may be more beneficial than later attempts to manage established disease. The key to guideline implementation is to improve the quality of risk assessment and demonstrate the association between risk factors, intervention, and reduced event rates. In the future, this may be made possible by means of automated data entry and various other measures. In conclusion, opportunities exist to increase guideline implementation in the primary care setting, with potential benefits for both the general population and healthcare resources.
  •  
44.
  • Zannad, Faiez, et al. (författare)
  • Risk stratification in cardiovascular disease primary prevention - scoring systems, novel markers, and imaging techniques
  • 2012
  • Ingår i: Fundamental and Clinical Pharmacology. - : Wiley. - 0767-3981 .- 1472-8206. ; 26:2, s. 163-174
  • Forskningsöversikt (refereegranskat)abstract
    • The aim of this paper is to review and discuss current methods of risk stratification for cardiovascular disease (CVD) prevention, emerging biomarkers, and imaging techniques, and their relative merits and limitations. This report is based on discussions that took place among experts in the area during a special CardioVascular Clinical Trialists workshop organized by the European Society of Cardiology Working Group on Cardiovascular Pharmacology and Drug Therapy in September 2009. Classical risk factors such as blood pressure and low-density lipoprotein cholesterol levels remain the cornerstone of risk estimation in primary prevention but their use as a guide to management is limited by several factors: (i) thresholds for drug treatment vary with the available evidence for cost-effectiveness and benefit-to-risk ratios; (ii) assessment may be imprecise; (iii) residual risk may remain, even with effective control of dyslipidemia and hypertension. Novel measures include C-reactive protein, lipoprotein-associated phospholipase A 2, genetic markers, and markers of subclinical organ damage, for which there are varying levels of evidence. High-resolution ultrasound and magnetic resonance imaging to assess carotid atherosclerotic lesions have potential but require further validation, standardization, and proof of clinical usefulness in the general population. In conclusion, classical risk scoring systems are available and inexpensive but have a number of limitations. Novel risk markers and imaging techniques may have a place in drug development and clinical trial design. However, their additional value above and beyond classical risk factors has yet to be determined for risk-guided therapy in CVD prevention. © 2012 The Authors Fundamental and Clinical Pharmacology © 2012 Société Française de Pharmacologie et de Thérapeutique.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 41-44 av 44
Typ av publikation
tidskriftsartikel (40)
forskningsöversikt (4)
Typ av innehåll
refereegranskat (41)
övrigt vetenskapligt/konstnärligt (3)
Författare/redaktör
De Backer, Guy (39)
Cifkova, Renata (18)
Dallongeville, Jean (16)
Banegas, José R (13)
Fagard, Robert (13)
Mancia, Giuseppe (13)
visa fler...
Perk, Joep (10)
Laurent, Stephane (10)
Reiner, Zeljko (10)
Guallar, Eliseo (10)
Borghi, Claudio (10)
Redon, Josep (10)
Narkiewicz, Krzyszto ... (10)
Kjeldsen, Sverre E. (10)
Zamorano, Jose Luis (9)
Viigimaa, Margus (9)
Rodríguez-Artalejo, ... (9)
Graham, Ian (9)
Ryden, Lars (8)
Zannad, Faiez (8)
Halcox, Julian P (8)
Schmieder, Roland E. (8)
Tendera, Michal (7)
Dean, Veronica (7)
Perk, Joep, 1945- (7)
Funck-Brentano, Chri ... (7)
Nilsson, Peter M (6)
Tubach, Florence (6)
Roy, Carine (6)
Sirnes, Per Anton (6)
Jaarsma, Tiny (5)
Widimsky, Petr (5)
Filippatos, Gerasimo ... (5)
Tuomilehto, Jaakko (5)
De Caterina, Raffael ... (5)
Dickstein, Kenneth (5)
Giampaoli, Simona (5)
Sleight, Peter (5)
Galderisi, Maurizio (5)
Pajak, Andrzej (5)
Amouyel, Philippe (5)
De Bacquer, Dirk (5)
Grobbee, Diederick E ... (5)
Silber, Sigmund (5)
Medina, Jesus (5)
Sechtem, Udo (5)
Grassi, Guido (5)
Camm, John (5)
Vahanian, Alec (5)
Tokgözoglu, Lale (5)
visa färre...
Lärosäte
Linnéuniversitetet (16)
Lunds universitet (12)
Göteborgs universitet (10)
Karolinska Institutet (9)
Umeå universitet (6)
Uppsala universitet (5)
visa fler...
Linköpings universitet (4)
Luleå tekniska universitet (2)
Stockholms universitet (1)
Högskolan Dalarna (1)
Sveriges Lantbruksuniversitet (1)
visa färre...
Språk
Engelska (43)
Italienska (1)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (36)
Naturvetenskap (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy